The Micronoma Team

Micronoma was founded by leaders in microbiome research with the goal of revolutionizing and advancing early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients’ needs are identified and addressed by their clinicians at the earliest stage, for a better chance to live longer, healthier lives.

Leadership

Sandrine Miller-Montgomery, Pharm.D, Ph.D.

Co-founder, Board Member, President, and CEO

Greg Sepich-Poore, Ph.D.

Co-founder, Chief Analytics Officer, Board Member

Rob Knight, Ph.D.

Co-founder, Scientific Advisory Board

Eddie Adams, Ph.D.

Chief Scientific Officer

Darryl Garrison

Chief Operating Officer

Todd Czerwinski

Todd Czerwinski

Vice President of Business Development

Board of Directors (5)

Chidozie Ugwumba

Symbiosis VC

Magda Marquet, Ph.D.

Chairman of the BOD, independant member

Wes-Winn

Wesley Winn

Symbiosis VC

Sandrine Miller-Montgomery, Pharm.D, Ph.D., President and CEO, and Greg Sepich-Poore, Ph.D., CAO

Scientific Advisory Board

Rob Knight, Ph.D.

Founding Director of the Center for Microbiome Innovation and Professor of Pediatrics, Bioengineering, and Computer Science & Engineering at UC San Diego. His work has linked microbes to a range of health conditions, has enhanced our understanding of microbes in environments, and has made high-throughput sequencing techniques accessible to thousands of researchers around the world.

Martin J. Blaser, M.D.

Chairman, Professor of Medicine and Pathology and Director of the Center for Advanced Biotechnology and Medicine, and holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University.

Leena Das-Young, Pharm. D.

C-suite executive for biopharma in oncology, infectious disease, liquid biopsy, and product development in complex disease and precision medicine settings, including executive roles at both Pfizer and Guardant Health.

Ravid Straussman, M.D., Ph.D.

Principal Investigator at the Weizmann Institute where his research is focused on understanding the roles of the tumor microenvironment and the tumor microbiome on resistance to cytotoxic, targeted, and immune-mediated anti-cancer therapies.

Jennifer Wargo, M.D., M.M.Sc.

Professor, Surgical Oncology & Genomic Medicine at The University of Texas MD Anderson Cancer Center in Houston. Dr. Wargo has led and published key research on the microbiome and the role it plays in patient response to cancer therapy.

Research Partners

Micronoma is proud to partner with many internationally recognized academic institutions and non-for profit entities. Together, we are uniquely poised to revolutionize early-stage cancer detection, and along with it, significantly improve patients’ lives.
UCL

Investors

Website Terms of Use, Privacy Policy, and Licenses

Micronoma, INC., CLIA #05D2253538

Oncobiota™ LDT is under development and is currently not available for commercial use in any jurisdiction. Once available under CLIA license, Oncobiota™ will be available in the United States by prescription only.

Contact Us

If you have questions or would like to learn more, please email us at info@micronoma.com or learn about joining our team at Careers.

Micronoma
6342 Ferris Square
San Diego, CA 92121